Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4299
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$29.32
Market Cap
$3.68B
Change (1 day)
1.91%
Change (1 year)
91.76%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Stock price history for Amylyx Pharmaceuticals, Inc. (AMLX)
Highest end of day price: $27.68 on 2026-10-01
Lowest end of day price: $19.75 on 2022-01-01
Lowest end of day price: $19.75 on 2022-01-01
Stock price history of Amylyx Pharmaceuticals, Inc. from 2022 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 41.20% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
